INDIVIDUAL PEPTIDE PROFILE
AOD-9604
A modified fragment of the human growth hormone molecule originally developed as an anti-obesity candidate, with human trial results that did not support its early promise.
WHAT IT IS
AOD-9604 is a synthetic peptide based on a short fragment near the C-terminal region of the human growth hormone molecule, the portion historically associated with fat metabolism in laboratory research.
It was developed as a deliberate attempt to isolate a fat-metabolism effect without the broader growth-promoting activity of full human growth hormone.
Development as an obesity drug did not succeed, and it has since appeared largely in wellness and gray-market settings rather than in clinical medicine. FDA status: AOD-9604 is not currently FDA-approved for any indication.
WHAT RESEARCHERS ARE STUDYING IT FOR
Research and development interest has centered on:
- Obesity and body-fat reduction, its original development target
- Lipolysis, the breakdown of stored fat
- Effects on body composition without growth hormone-like signaling
- Later exploratory work in cartilage and osteoarthritis models
HOW IT WORKS / MECHANISM BEING STUDIED
In laboratory and animal research, the growth hormone fragment AOD-9604 is derived from was reported to stimulate lipolysis and reduce lipogenesis in fat tissue.
Importantly, AOD-9604 was designed not to meaningfully raise IGF-1 or produce the insulin-resistance and tissue-growth effects associated with full human growth hormone. In human studies it has not shown the growth-promoting activity of hGH.
That design goal is the central premise of the compound, which is also why the human efficacy results are notable: the mechanism observed in the lab did not translate into meaningful clinical outcomes.
HOW IT DIFFERS FROM hGH AND FROM GLP-1 / GIP MEDICATIONS
Full human growth hormone is a complete 191-amino-acid protein that raises IGF-1 and affects growth, body composition, glucose handling and multiple tissues. AOD-9604 is a short fragment intentionally stripped of that broader activity.
Modern GLP-1 and GIP medications such as semaglutide and tirzepatide work through an entirely different pathway. They act on appetite regulation, satiety signaling and glucose-dependent insulin release, and they have produced substantial, well-documented weight loss in large randomized trials leading to FDA approval.
AOD-9604 belongs to neither category in terms of evidence.
POTENTIAL AREAS OF RESEARCH INTEREST
- Whether targeted fat-metabolism signaling can be separated from growth signaling
- Localized or joint-related applications explored in later research
- Historical lessons about translating animal lipolysis data into human outcomes
WHAT THE EVIDENCE ACTUALLY SHOWS
Animal and laboratory research reported favorable effects on fat metabolism, which is what generated the original commercial interest.
Human clinical trials in overweight and obese participants did not demonstrate clinically meaningful weight loss compared with placebo. Tolerability was generally acceptable, but efficacy did not reach the threshold needed, and development as an obesity drug was discontinued.
AOD-9604 has appeared on lists of substances of concern in sport and in FDA discussions of bulk substances used in compounding. It has not been shown in human research to confirm the weight-loss effect it is sometimes marketed for.
Animal data vs. human outcomes
A CASE STUDY IN WHY HUMAN TRIALS MATTER
AOD-9604 had a clean scientific story: isolate the fat-burning fragment, leave the growth signaling behind.
The animal research supported that story. The human trials did not deliver meaningful weight loss.
The marketing that still surrounds this compound largely cites the earlier laboratory rationale rather than the human results that followed.
Research Reality Check
What we know
AOD-9604 is a modified fragment of human growth hormone, designed to promote lipolysis without hGH-like growth signaling, and it has been studied in human clinical trials with generally acceptable tolerability.
What remains uncertain
Nothing about clinically meaningful weight loss has been established. Human trials did not show significant benefit over placebo, it is not FDA-approved, and long-term safety outside of trial settings is unknown.
Educational commentary, not personal testimonial
The Balanced Body Lifestyle Take
AOD-9604 has our attention because it grew out of growth hormone research with a focus on fat metabolism rather than growth signaling. That narrow, targeted idea is an interesting direction, and we like keeping an eye on where it leads.
If AOD-9604 has caught your attention or you would like to understand it better, reach out to us. We can talk about what drew you to it, work through your questions, and look at what is happening in the wider peptide world.
QUESTIONS PEOPLE OFTEN ASK
SOURCES & FURTHER READING
- PubMed: AOD-9604 human and preclinical research literature
- Heffernan et al., research on the growth hormone C-terminal fragment and fat metabolism
- U.S. Food and Drug Administration: Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks
- World Anti-Doping Agency: Prohibited List
Peptide Education Consultation
Interested in learning more about peptides? Schedule an educational consultation with Vince Angelo to discuss the information and ask questions.
Schedule an Educational ConsultationEDUCATIONAL NOTICE
The Balanced Body Lifestyle™ provides peptide and wellness information for educational purposes only. Content is intended to help readers better understand emerging research, established evidence and areas of scientific uncertainty. It is not medical advice, diagnosis, treatment guidance or a recommendation to use any medication, peptide or research compound. Decisions involving prescription medications or investigational compounds should be discussed with a qualified healthcare professional.
THE BALANCED BODY LIFESTYLE
A healthy life is built on balance.